LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

This study is testing whether low-dose radiation to the liver combined with chemotherapy and immunotherapy can help people with nasopharyngeal carcinoma (a cancer at the back of the nose and throat) that has spread to the liver. Low-dose radiation is used here to potentially help the immune system respond better to the other treatments. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with a specific type of nasopharyngeal cancer (WHO Type II or III) that has spread to the liver - You either have newly diagnosed disease with liver spread, or previously treated disease that spread to the liver more than 6 months after finishing radical treatment - You are reasonably fit (ECOG 0-1) and have at least one measurable tumor - Your blood counts, liver, and kidney function meet required levels **You may NOT be eligible if...** - Your cancer has come back at the original site (nasopharynx) and you previously had full-dose radiation there - You previously received immune checkpoint therapy (e.g., PD-1/PD-L1 inhibitors) - You have an active autoimmune disease - You have had major surgery within 28 days, a recent heart attack, or serious heart failure - You have HIV, uncontrolled hepatitis B or C, or active tuberculosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.